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http://www.resource-allocation.com/content/12/1/3RESEARCH Open AccessBudget constraint and vaccine dosing:
a mathematical modelling exercise
Baudouin A Standaert1,2*, Desmond Curran1† and Maarten J Postma2†Abstract
Background: Increasing the number of vaccine doses may potentially improve overall efficacy. Decision-makers
need information about choosing the most efficient dose schedule to maximise the total health gain of a
population when operating under a constrained budget. The objective of this study is to identify the most efficient
vaccine dosing schedule within a fixed vaccination budget from a healthcare payer perspective.
Methods: An optimisation model is developed in which maximizing the disease reduction is the functional
objective and the constraint is the vaccination budget. The model allows variation in vaccination dosing numbers,
in cost difference per dose, in vaccine coverage rate, and in vaccine efficacy. We apply the model using the
monovalent rotavirus vaccine as an example.
Results: With a fixed budget, a 2-dose schedule for vaccination against rotavirus infection with the monovalent
vaccine results in a larger reduction in disease episodes than a 3-dose scheme with the same vaccine under most
circumstances. A 3-dose schedule would only be better under certain conditions: a cost reduction of >26% per
dose, combined with vaccine efficacy improvement of ≥5% and a target coverage rate of 75%. Substantial
interaction is observed between cost reduction per dose, vaccine coverage rate, and increased vaccine efficacy.
Sensitivity analysis shows that the conditions required for a 3-dose strategy to be better than a 2-dose strategy may
seldom occur when the budget is fixed. The model does not consider vaccine herd effect, precise timing for
additional doses, or the effect of natural immunity development.
Conclusions: Under budget constraint, optimisation modelling is a helpful tool for a decision-maker selecting the
most efficient vaccination dosing schedule. The low dosing scheme could be the optimal option to consider under
the many scenarios tested. The model can be applied under many different circumstances of changing dosing
schemes with single or multiple vaccines.
Keywords: Rotavirus, Vaccination, Economic evaluation, Budget optimisation modellingBackground
The initial dosing schedule of a new vaccine is based on
the results obtained in randomised clinical trials which
evaluate the efficacy at the individual level. When real-
world data on effectiveness become available questions
may be raised over whether the initial dosing schedule is
the most appropriate one to achieve the maximum benefit
at the population level from limited available healthcare* Correspondence: baudouin.a.standaert@gsk.com
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reproduction in any medium, provided the orresources. This is an interesting economic question in
which the number, timing and efficacies of vaccine doses
should be assessed in detail. In the analysis presented here
we evaluate the impact of a change in number of vaccine
doses and the economic value of such a change under the
constraint of a fixed vaccine budget, a situation most likely
to occur in low-income countries. We have used the
monovalent rotavirus vaccine (Rotarix®a) as a concrete ex-
ample as it has recently been suggested that the number
of doses for this vaccine should be increased in low-
income countries [1].
Rotavirus infection results in a high burden of acute
gastroenteritis disease in children, especially in low-
income countries, with approximately 450,000 deathsral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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There are currently two vaccines available against rota-
virus [3], but all analyses here performed are presented
with the 2-dose attenuated single human rotavirus strain
monovalent rotavirus vaccine (Rotarix®) [4,5].
In 2009 the World Health Organization recommended
the inclusion of rotavirus vaccination in routine immu-
nization programs worldwide [6]. However, trials and ob-
servational studies conducted in low-income countries
have reported lower vaccine efficacy than in high-income
countries [7-9]. Many hypotheses have been formulated to
explain this, but no definitive conclusions have been
drawn [10,11]. Nevertheless, the morbidity and mortality
impact expected in low-income countries greatly surpasses
that in high-income countries, despite the lower inferred
vaccine efficacy [12].
To improve the results of vaccination it has been re-
cently suggested that adding one dose to the existing vac-
cine dosing schedule could improve overall vaccination
efficacy [1]. However this is by no means certain as 3-
dose vaccine efficacy studies with other rotavirus vaccine
products tested in low-resource environments have also
reported lower efficacy estimates compared with wealthier
settings [13,14]. In low-income countries where healthcare
budgets are tight, a 2-dose schedule could be a more effi-
cient option than a 3-dose schedule as fewer administra-
tions may reduce the overall vaccination cost [15].
Administration may be particularly expensive in those
countries, as the costs of the logistics required to maintain
a cold chain may be high [16,17]. A 2-dose schedule may
also achieve improved compliance and completion of the
total dosing at an earlier time point as it obviously requires
fewer doses to obtain full vaccination compared with a 3-
dose schedule [18].
Given the considerations above, administering an
additional dose could improve the rotavirus vaccine effi-
cacy, but it raises an economic question of whether
this would provide acceptable added value. Traditional
health economic analysis would calculate the incremen-
tal cost-effectiveness ratio (ICER) to explore whether
the additional dose is cost-effective compared with the
current 2-dose schedule. If the analysis indicates that
the extra budget needed for reaching the extra benefit is
acceptable under the local constraints, it then requires
that extra budget is found to secure the implementation of
this new intervention. However, in low-income countries
there may be no extra budget available to administer the
additional vaccine dose even if it would be cost-effective.
In such environments, the addition of an extra vaccine
dose may be possible only at the expense of cuts elsewhere
in the fixed budget. Conversely, it may be possible to im-
prove the clinical results by increasing the vaccine cover-
age rate without adding an extra dose. Therefore, it may
be more appropriate to consider a different economicapproach and to compare the clinical outcomes ob-
tained with a 2-dose schedule with a higher vaccine
coverage rate versus the clinical outcomes obtained
with a 3-dose schedule at a higher vaccine efficacy but a
lower coverage rate. In other words, given a fixed
budget, when would it be efficient to move to a 3-dose
strategy? The solution to this question is no longer
driven by a cost-effectiveness threshold but by the
fixed budget: what is the best way to spend money
under a fixed budget in order to obtain a maximum
health benefit? This type of question can best be ana-
lysed at the population level (accumulated benefit and
cost), in contrast to cost-effectiveness analysis that can
be assessed at the individual level. It also seems to be a
realistic way for local decision-makers to evaluate the
benefit of vaccination strategies [19].
In this paper we evaluate the potential cost and health
effect of adding a third dose to the existing 2-dose sched-
ule of the monovalent rotavirus vaccine in low-income
countries, using a hypothetical model to explore this. The
model uses optimisation theory, in which a wide range of
scenarios are explored to find the optimum solution under
budget constraint. In sensitivity analysis, we investigate
the influence of several variables on the results, including
vaccine efficacy, coverage rate, and price per dose.
Methods
The economic question raised in the introduction, “what
is the best way to spend a fixed budget to obtain the
maximum health benefit from vaccination?” can best be
explored using optimisation or mathematical program-
ming models [20]. The exercise is to reach specific
(functional) objectives or goals under certain constraints.
In this setting, the objective function is to maximise
health benefits. The model has been programmed to
evaluate just one particular disease with one intervention
type, but different diseases with different interventions
assessing a same outcome could be considered as well.
In the particular case of rotavirus disease, the outcome
measure, used to assess the benefit, is the total number of
diarrhoea events in the population of children aged <5 years,
and the objective is to minimise the number of such events.
As a direct consequence of this, mortality and hospitalisa-
tion rates due to rotavirus disease would also be reduced.
We conducted a cross-sectional analysis with an annual
budget, estimating events per year in the at-risk popula-
tion at steady-state. The latter typically reflects the situ-
ation when disease spread and vaccine efficacy have
reached their equilibrium across the entire at-risk popula-
tion. The model constraints are:
 Annual vaccination budget is fixed;
 Vaccine efficacy for a 3-dose strategy ≥ than that for
a 2-dose strategy;
Table 1 Input variables
Parameter Value
Total vaccination budget $200,000
Cost/dose for 2-dose vaccine schedule (strategy A) $13.00
Cost/dose for 3-dose vaccine schedule (strategy B) $10.00
Diarrhoea incidence rate per child per year 0.30
Vaccine efficacy for 2-dose vaccine schedule (strategy A) 0.60
Vaccine efficacy for 3-dose vaccine schedule (strategy B) 0.65
Number of vaccine doses for strategy A 2
Number of vaccine doses for strategy B 3
Population 10,000
Target vaccine coverage rate 75%
Average treatment cost per diarrhoea event $50.00
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for a 2-dose strategy;
 Cost per dose for a 3-dose strategy < than that for a
2-dose strategy;
The model assumes a fixed cost per dose for the admin-
istration and for the logistics to maintain the cold chain.
The coverage rate allows a variation between 0% and
100%. No discounting is applied as it concerns a budget
analysis.
The model construct is developed in Microsoft Excel,
using additional Solver tools (Frontline Systems, Inc.)
from software specifically designed to be integrated as
an add-in into Microsoft Excel. The results of the opti-
misation model indicate which strategy (i.e. a 2- or 3-
dose strategy) would produce maximum health benefits
under a budget constraint. The analysis is conducted
from the perspective of the healthcare payer system. A
copy of the model is available as a Microsoft Excel
spread sheet (see Additional file 1).
As the current exercise is hypothetical we do not apply
it to a specific country. The whole analysis is focussed
on the relationships between the critical variables and
their relative values.
Sensitivity analysis is conducted by varying three key
parameters that affect the results, vaccine efficacy, price,
and coverage. The relationships between the variables
are as follows: the number of overall diarrhoea events
avoided by a 2-dose schedule (y) is a function of the vac-
cine coverage rate (a), the vaccine efficacy (x) obtained,
and the disease population incidence rate (i):
y ¼ a  x  i
The increment (c) to reach the objective function
(maximising the reduction in diarrhoea events) with a 3-
dose schedule is a function of the change in the vaccine
coverage rate (a1) and the extra vaccine efficacy (x1) ob-
tained, compared with a 2-dose schedule, while the
population incidence rate remains unchanged:
y þ c ¼ aþ a1ð Þ  xþ x1ð Þ½   i
The change in coverage rate (a1) was assumed
dependent on the relative price difference per dose be-
tween a 2- and a 3-dose vaccine schedule, given a fixed
budget for vaccination. There will automatically be a link
with the reduction in vaccine coverage rate, if the price
difference per dose and per vaccine scheme decreases,
as an increase in the vaccine efficacy (x1) is then re-
quired for the 3-dose schedule to keep its advantage
over the 2-dose schedule. Sensitivity analysis should
demonstrate what price difference, what vaccine cover-
age rate, or what vaccine efficacy difference would be re-
quired to achieve a change in the preference betweenthe two dosing schedules. In addition, the change in health
outcomes will affect the overall management cost of the
disease. Changes in vaccine coverage rate and/or vaccine
efficacy would be expected to affect the cost drivers for
overall disease management costs, such as hospitalisation
rate. To address this, we add an evaluation of the budget
change for overall disease management as a relative value
to the fixed budget for vaccination as an additional output
variable in the sensitivity analysis.
Results
Analysis with fixed data
Tables 1 and 2 provide an example to illustrate the model.
Table 1 shows the input data and Table 2 the modelled out-
puts. This hypothetical example assumed an annual birth
cohort of 10,000 children who could be vaccinated. Based
on the assessment of disease burden and the financial prior-
ities, the health ministry is assumed to have allocated an
annual budget of $200,000 for rotavirus vaccination. The
annual incidence rate of rotavirus diarrhoea without vaccin-
ation was set at 0.3 per child per year for the at-risk period
(from birth up to age 5 years) of the birth cohort, thus an
average of 3,000 children per year would be expected to de-
velop diarrhoea without vaccination.
Under strategy A (na = 2) the cost per dose was set to
$13, and thus the cost per course of vaccination was $26
(=$13*2). With a target coverage rate of 75%, the cost of
vaccination was estimated at $195,000 (=10,000*0.75*
$26) which represents 97.5% of the total available vac-
cination budget. As such, there would be sufficient
budget (i.e. the budget would not be exceeded) and the
target coverage rate would be reached. Assuming a vac-
cine efficacy of 60%, 900 of the 7,500 children in the vac-
cinated part of the cohort would be expected to develop
diarrhoea, in addition to 750 of the 2,500 children in the
unvaccinated part of the cohort, yielding a total of 1,650
diarrhoea cases. Thus, the health benefit gained by vac-
cination with a 2-dose schedule would be a reduction of
Table 2 Modelled outputs
Output variable 2- dose schedule (strategy A) 3- dose schedule (strategy B)
Value % Value %
Number of diarrhoea events expected with no vaccination 3000 3000
Vaccine cost $195,000 $225,000
Vaccine cost as % of available vaccination budget 97.5% 112.5%
Budget shortfall 0 $25,000
Number of people in target population not covered because of insufficient budget 0 833
Vaccine efficacy difference 5%
Vaccine cost difference 23.1%
Number of people covered by current budget 7500 6667
Number of diarrhoea events in vaccinated children 900 700
Number of diarrhoea events in non-vaccinated children 750 1000
Total number of diarrhoea events with vaccination 1650 1700
Treatment cost $82,500 $85,000
Gain (reduction in diarrhoea events compared with no vaccination) 1350 45.0% 1300 43.3%
Total cost $277,500 $285,000
Using the input variables shown in Table 1.
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birth cohort, compared with no vaccination (Table 2).
Under strategy B (nb = 3), the cost per dose was set
to $10 and thus the cost per course of vaccination
was $30 (=$10*3). With the same target coverage rate
of 75%, the total cost of vaccination would be $225,000
(=10,000*0.75*$30), representing 112.5% of the vaccin-
ation budget. Thus, there would be insufficient budget
(a shortfall of $25,000). This shortfall implies that the
budget would have run out with 833 children among the
targeted population still to be vaccinated ($25,000/$30 =
833), and thus the available budget would be sufficient to
vaccinate 6,667 children. Assuming a vaccine efficacy for
the 3-dose schedule of 65%, 700 of the 6,667 children in
the vaccinated part of the cohort would still develop diar-
rhoea, in addition to 1,000 of the 3,333 children in the un-
vaccinated part of the cohort, yielding a total of 1,700
diarrhoea cases. Thus, the health benefit gained by vaccin-
ation using a 3-dose schedule would be a reduction of
1,300 diarrhoea cases (a reduction of 43.3%), compared
with no vaccination (Table 2).
Comparing the two strategies, although the cost per
dose was 23% lower with a 3-dose schedule (strategy
B), the cost per course was higher ($30 vs $26). The 2-
dose schedule (strategy A) was not only cheaper overall
($195,000 vs. $200,000), but also resulted in a greater
reduction in diarrhoea events (45% vs 43.3%), despite
having a lower vaccine efficacy than the 3-dose sched-
ule. This is because the lower cost per course with the
2-dose schedule would allow more children to be vac-
cinated within the available allocated budget.Sensitivity analysis
Figures 1, 2, and 3 show the results of sensitivity ana-
lyses for a wide range of values tested.
Figure 1 presents the relationship between price per
dose and the reduction in diarrhoea events and the total
cost of vaccination under the assumptions listed in the le-
gend. Consistent with the illustrative example shown in
Table 2, with a 2-dose schedule a 45% reduction in diar-
rhoea events would be observed at a cost of 97.5% of the
vaccination budget. Allowing the cost per dose for strategy
B to vary, the figure illustrates that a large cost difference
per dose of >33.3% would be required before the 3-dose
schedule would become less costly; this occurs at the point
at which the dash dotted line (− . –) crosses the dashed
line (− −). A high cost difference per dose (>25.9%
cheaper) would also be required for the 3-dose schedule
to achieve a larger reduction in diarrhoea events than the
2-dose schedule; this occurs when the dotted line (…)
crosses the solid line. Thus, a 2-dose vaccine schedule
would always be the better choice when the relative cost
difference does not exceed 25.9%.
There is a small area between a cost difference per dose
of 25.9% and 33.3% where a larger reduction in diarrhoea
events would be observed at a total vaccination cost
within the fixed budget using the 3-dose strategy, while
still remaining at the vaccine coverage rate of 75%. This
area varies depending on other factors such as the vaccine
efficacy difference. In situations where the 3-dose vaccine
is cheaper, no additional reduction in diarrhoea events






































































Vaccine relative cost difference (%) per dose
% overall reduction 2
doses
% overall reduction 3
doses
% change of fixed
vaccine budget 3
doses
% change of fixed
vaccine budget 2
doses
Figure 1 Effect of the difference in vaccine cost per dose on budget and effect. Reduction in diarrhoea events (left Y-axis) and relative
change of vaccine budget constraint (=100%) (right Y-axis) as a function of the relative cost difference per vaccine dose. Assumptions: vaccine
budget, $200,000; 2-dose vaccine efficacy (strategy A), 60%; 3- dose vaccine efficacy (strategy B), 65%; target vaccine coverage, 75%; 2-dose
vaccine cost per dose (strategy A), $13.00; 3- dose vaccine cost per dose (strategy B), allowed to vary.
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diarrhoea event, set at $50 per event, to estimate an overall
cost for disease management (vaccination plus the cost of
treating cases) with a vaccination cost of $195,000. For
example, in Table 2, 1,650 cases of diarrhoea would beFigure 2 Effect of vaccine efficacy on total cost and effect. Total cost (
function of vaccine efficacy. Assumptions: vaccine budget, $195,000; 2-dose
allowed to vary; target vaccine coverage, 75%; 2-dose vaccine cost per dosexpected to occur with the 2-dose schedule, and the cost of
treating these cases would be $82,500 (=1,650*$50).
The total cost of the 2-dose strategy A would therefore
be $277,500 (vaccine cost of $195,000 + cost of treating
cases of $82,500). This value is 42.3% higher than theright Y-axis) and effect (reduction in diarrhoea events, left Y-axis) as a
vaccine efficacy (strategy A), 75%; 3-dose vaccine efficacy (strategy B),
































































Target vaccine coverage rate (%)
% overall reduction 2 doses
% overall reduction 3 doses
% additional cost 2 doses
% additional cost 3 doses
Figure 3 Effect of target vaccine coverage rate on total cost and effect. Total cost (right Y-axis) and effect (reduction in diarrhoea events, left
Y-axis) as a function of target vaccine coverage rate. Assumptions: vaccine budget, $200,000; 2-dose vaccine efficacy (strategy A), 60%; 3-dose
vaccine efficacy (strategy B), 65%; 2-dose vaccine cost per dose (strategy A), $13.00; 3-dose vaccine cost per dose (strategy B), $10.00; target vac-
cine coverage, allowed to vary.
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a vaccine efficacy of 60% a 45% reduction in diarrhoea
events (solid line) could be achieved at a total disease
management cost of 42.3% (dashed line) over the vac-
cination budget. Assuming a vaccine efficacy of 90%, a
67.5% reduction in diarrhoea events (solid line) could
be achieved at a total disease management cost of 25%
(dashed line) over the vaccination budget.
In Figure 2, it may appear counter-intuitive that a higher
vaccine efficacy is needed with a 3-dose strategy versus a
2-dose vaccination strategy to obtain the same overall re-
sult. This reflects the higher vaccine coverage rate that
can be achieved with a 2- dose vaccine strategy under
budget constraint. In addition, the total budget would al-
ways be lower with a 2-dose schedule than with a 3-dose
schedule when the difference in price per dose is lower
than 33.3% (as shown in Figure 1 and discussed above).
Figure 3 demonstrates the effect of target coverage
rate on the budget increment and the avoided diarrhoea
events. On the left-hand side of the graph, where the tar-
get coverage rate is low, there would be sufficient budget
for both strategies. Thus, the 3-dose strategy would pre-
vent more cases (due to its higher efficacy) but at a
higher cost. The cost for the 3- dose strategy (dash-dot-
ted line) would exceed that for the 2-dose strategy
(dashed line) at all coverage rates modelled. However, as
coverage increases the number of events prevented by
the 2-dose strategy (solid line) would overtake the num-
ber of events prevented by the 3-dose strategy (dotted
line). This is because the maximum coverage rate
achievable within the fixed budget would be higher for
the 2-dose schedule (75%) than for the 3-dose schedule(66.7%). Thus, on the right-hand side of the graph where
target coverage is high, the 2-dose schedule would prevent
more cases than the 3-dose schedule at a lower cost.
Discussion
The results of the modelling exercise presented here indi-
cate that when the vaccination budget is constrained a 2-
dose schedule for vaccination against rotavirus infection
with the monovalent rotavirus vaccine would be expected
to produce a larger reduction in disease events than a 3-
dose schedule in most circumstances when using the same
vaccine. This reflects the higher coverage rate that can be
achieved with a 2-dose schedule than with a 3-dose sched-
ule within a fixed budget. According to the model the 3-
dose schedule would produce results superior to the 2-dose
schedule only under the following conditions: large im-
provement in vaccine efficacy for the 3- dose schedule
compared with the 2-dose schedule; large reduction in cost
per dose for the 3-dose schedule compared with the 2-dose
schedule; low target vaccine coverage rate. The effects of
these parameters are closely intertwined. So a situation in
which the 3-dose strategy would become superior to the 2-
dose strategy may be achieved by a large change in one par-
ameter alone, or by smaller changes in several parameters
in combination. We will discuss each parameter separately.
A study in Africa reported vaccine efficacy against se-
vere rotavirus gastroenteritis of 63.7% for a 3-dose sched-
ule and 58.7% for a 2-dose schedule [21], a difference of 5
percentage points. However, it remains uncertain whether
adding an extra dose truly improves the overall vaccine ef-
ficacy, as 3-dose vaccine efficacy studies using other vac-
cine products/candidates in low-resource environments
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ier settings [13,14]. The difference in vaccine efficacy in
our model was similar to the difference observed in the
African study (65% versus 60%). Our results indicated that
this magnitude of improvement in efficacy with the 3-dose
strategy would result in an overall health gain (fewer diar-
rhoea events) compared with the 2-dose schedule only
with a cost per dose for the 3-dose schedule of at least
25.9% lower than the cost per dose for the 2-dose sched-
ule. The exact value will vary depending on the absolute
vaccine efficacy values used, the budget available and the
vaccine coverage rate, and thus will vary according to local
circumstances. The smaller the gain in vaccine efficacy,
the larger the cost difference per dose required.
Vaccine prices are often negotiated according to the
total number of doses ordered by a country. An order for
60,000 doses intended to implement a 3-dose strategy cov-
ering 20,000 people may vary relatively little in price com-
pared with an order also for 60,000 doses intended to
implement a 2-dose strategy covering 30,000 people. Use
of a budget optimisation tool may help decision-makers to
identify the optimal strategy in their local environment,
taking into account any changes in price as well as the ex-
pected change in vaccine efficacy and coverage.
The results presented here suggest that a 2-dose schedule
is likely to be the optimal strategy, due to a higher vaccine
coverage rate that the given budget allows. However, the
vaccination budget is not the only factor influencing cover-
age rates. Other factors may include education, religious be-
liefs, attitudes to complementary and alternative medicine,
gender-based inequity, civil unrest, the percentage of the
population living in urban versus rural areas, accessibility of
vaccination and other healthcare programmes, and financial
factors [22-25]. Such issues are not insurmountable and
high vaccine coverage rates can be achieved in low-income
countries, as illustrated by high 3-dose diphtheria-tetanus-
pertussis coverage rates in Kenya, Bangladesh and Sri
Lanka [26]. Other interventions beyond the vaccination
programme may be needed to improve the coverage rate,
such as health education, better transportation, reduction
in communication barriers to vaccinations, outreach to reli-
gious leaders and financial incentives.
Many studies have investigated the problem of optimal
vaccine dosing schedules. Some have addressed the ques-
tion from the opposite direction, evaluating whether a
smaller number of doses can achieve the same clinical out-
comes. For example, a 2-dose-plus-booster schedule for
pneumococcal vaccination is accepted as having similar ef-
ficacy to a 3-dose-plus-booster schedule [27]. In the
present analysis, as the effectiveness of the 2-dose rota-
virus vaccine appears to be reduced in low-income coun-
tries the relevant question is whether adding one dose
could improve clinical results. The strength of the model
presented here is that it explicitly recognises the reality ofa fixed budget. Adding an extra dose requires increasing
the number of doses per vaccinee. Under a fixed budget
this either requires an equivalent reduction in price to
cover the same number of people or a corresponding re-
duction in coverage, or a combination of the two. An opti-
misation model can explore the question of whether
increasing vaccine efficacy by adding an extra dose, or in-
creasing coverage by using a 2-dose schedule, would be
the best strategy to maximise the population health gains.
It can also quantify the extra budget that would be re-
quired to achieve a larger health gain, providing a trans-
parent method of assessing the best strategy for managing
disease burden.
The model presented here could be applied to any ques-
tion about the optimal dose schedule for any vaccine. For
instance, the potential switch from a 2-dose to a 1-dose
schedule for hepatitis A in Latin America is an important
decision that requires careful choice of the optimal admin-
istration schedule [28]. The modelling exercise outlined
here could provide useful guidance on this question that
may be helpful for decision-makers. Additional refine-
ments may be needed, as the present analysis did not use
a dynamic model and did not consider the potential effect
of an additional vaccine dose on herd protection, or differ-
ential waning rates for a 1-dose versus a 2-dose vaccine.
The model is simple in its construction and therefore
has some limitations. For example, it does not take ac-
count of herd effects which may be important when con-
sidering the impact of changes in coverage. The higher
coverage achievable with a 2-dose schedule compared
with a 3-dose schedule within a fixed budget may lead to
greater herd protection and thus to a larger difference in
health benefit than estimated in the present model. Fur-
thermore, the model does not cover changes in the timing
of doses, effects of disease spread before the final dose, or
natural immunity. In the case of rotavirus infection, nat-
ural immunity that develops with repeated infections is a
competitor to vaccine-induced immunity, leading to a pro-
gressive reduction in the scope for vaccination to provide
protection over time [29]. The model also does not take ac-
count of factors such as logistics and access to healthcare
facilities to administer the additional dose[16]. However, in
case of working under a fixed budget and increasing the
number of doses per person, extra administration cost
could be limited as a same person who already received
vaccine doses will get an additional one. Things could be
dramatically different with the reduction of the number of
doses per person. The extra administration cost could then
be much higher than in the previous situation because one
has to reach additional people (increase the coverage rate)
with the extra doses available.
Finally, we opted for a limited perspective in the ana-
lysis, namely the health care payer. We thought that es-
sentially these people are most interested in the results
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spective would only indicate that if a lower vaccine
coverage rate was achieved with a 3-dose program, the
societal cost could increase.
The optimisation approach here presented is very dif-
ferent from cost-effectiveness analysis. Cost-effectiveness
analysis estimates the incremental cost per unit of incre-
mental benefit to calculate an ICER value, and compares
it with a threshold value considered to represent accept-
able cost-effectiveness. However, to be meaningful this
threshold must be locally defined, taking account of local
circumstances. If the threshold is uncertain, the esti-
mated ICER for an intervention may be of limited value
in making a decision. Even if the threshold value is ac-
cepted, the ICER may not take account of infrastructure
expansions required to implement an intervention. For
example, a vaccination programme requiring a large in-
crease in cold-chain capacity could be challenging for
low-income countries, which in turn could result in a
delay to vaccine introduction with consequences for ex-
pected health outcomes. Furthermore, an intervention
requiring a substantial increase in expenditure – as may
be likely with mass population interventions such as vac-
cination – may exceed the budget available, in which
case it may be impractical to implement no matter how
favourable the ICER.
The biggest difference between a cost-effectiveness
analysis and an optimisation modelling is that in the
latter it can take into account the coverage rate as an
important variable to reach a certain health goal. In a
cost-effectiveness analysis with a static model the vac-
cine coverage rate may not influence the ICER per se.
This is different for a budget impact analysis where the
vaccine uptake expressed through the coverage rate
will impact the budget cycles. However budget impact
analysis only informs about the financial spread over
time and is not particularly linked to the goal or ob-
jective to be achieved within a defined period as opti-
misation modelling is pursuing.
Optimisation modelling, as presented in the exercise
here, is clearer and simpler to understand [19]. Instead
of a threshold value, it identifies the strategy that offers
the largest health gain (in the case of a preventive inter-
vention, the lowest number of disease events) within a
fixed budget. This more closely reflects the reality of
healthcare decisions. The number of available healthcare
interventions continually increases, yet national health-
care budgets are not unlimited. It can be applied to sim-
ple problems such as the comparison between a 2-dose
and 3-dose schedule for rotavirus vaccination illustrated
here, or more complex issues such as human papilloma-
virus vaccination [20]. We may even consider the assess-
ment of different vaccines against different diseases in
order to prioritize their indication within a clear budgetand time frame such as a multi-year vaccine portfolio
management program [30].
Further research will be valuable to refine the simple
model described here to take account of more complex
issues such as herd protection effects or multi-criteria
decision analysis designs.
Conclusions
Optimisation modelling indicates that within a fixed
budget and for the monovalent rotavirus vaccine, a 2-dose
vaccine schedule would be expected to provide better
health outcomes in most circumstances than a 3-dose
schedule. The model can be used to quantify the condi-
tions of changing dose schedules that would be optimal
for any vaccine. It is a more transparent and powerful
technique than the more conventional cost-effectiveness
analysis for evaluation of the economic questions faced by
decision-makers, because it explicitly recognises the
budget constraint that is a reality in most healthcare sys-
tems around the world.
Endnote
aRotarix is a registered trade mark of the GlaxoS-
mithKline group of companies.
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manuscript with the original input values, as a Microsoft Excel
workbook.
Abbreviation
ICER: Incremental cost-effectiveness ratio.
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